Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14583034 | 1.00 | NR1H2 (0.34) | NR1H2MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL4307305 | 0.91 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL30536042 | 0.90 | HSD17B10 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL13305792 | 0.90 | HSD17B10 (0.36) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4304666 | 0.83 | CHRM2 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4301159 | 0.78 | CTSK (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL1948727 | 0.77 | HSD17B10 (0.39) | NR1H2MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL31374926 | 0.77 | ELANE (0.37) | — | |
| SCHEMBL16843376 | 0.75 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL14451046 | 0.75 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119306790-A | Amide derivative, composition and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023116734-A1 | FUSED PYRROLIDINE COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-06-29 | — | — | WO | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | NR1H2 2620/4885MAPK1 3042/4885CHRM2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.